Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000411312 | SCV000486924 | likely pathogenic | Glycogen storage disease, type V | 2016-09-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000411312 | SCV002293549 | pathogenic | Glycogen storage disease, type V | 2024-10-03 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 14 of the PYGM gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PYGM are known to be pathogenic (PMID: 8316268, 16786513). This variant is present in population databases (rs747513238, gnomAD 0.02%). Disruption of this splice site has been observed in individuals with glycogen storage disease type V (GSD V), also known as McArdle disease (PMID: 8279469, 22250184, 30415384). ClinVar contains an entry for this variant (Variation ID: 371363). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000411312 | SCV002812667 | likely pathogenic | Glycogen storage disease, type V | 2023-12-23 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000411312 | SCV004207265 | likely pathogenic | Glycogen storage disease, type V | 2024-03-27 | criteria provided, single submitter | clinical testing |